Pharvaris announced that Phase 3 RAPIDe-3 trial results for deucrictibant IR, an oral bradykinin B2 receptor antagonist for on-demand treatment of hereditary angioedema (HAE) attacks, were published in The Lancet. The drug achieved symptom relief in 1.28 hours and complete resolution in 11.95 hours, met its primary endpoint and all 11 secondary endpoints, and showed a well-tolerated safety profile. An NDA with the FDA (PDUFA target date April 23, 2027) and MAA with the EMA are currently under regulatory review.

Pharvaris-funded analysis of real-world HAE management reveals significant gaps between guideline-recommended care and clinical practice. Study of 225 physicians and 279 patients identified key barriers to treatment adherence, including treatment burden, route of administration, and patient perception of attack severity. Findings highlight unmet needs and suggest oral daily treatment is preferred over injectable options, supporting Pharvaris' development of oral bradykinin B2 receptor antagonists.

Pharvaris announced publication of a qualitative study assessing disease burden in AAE-C1INH patients and validating patient-reported outcome measures. The study findings informed the design of the ongoing Phase 3 CREAATE trial investigating deucrictibant for prophylaxis and on-demand treatment of AAE-C1INH attacks. Results demonstrated significant multifaceted disease burden with frequent painful attacks disrupting daily life, and validated the use of established PRO instruments for measuring treatment benefits.

Pharvaris director Johannes Schikan sold 37,600 shares worth $1.3 million in late June 2026, representing 10.66% of his direct holdings. The sale occurred under a Rule 10b5-1 trading plan following a 96.5% one-year stock price appreciation. Shortly after, the FDA accepted the company's New Drug Application for its lead drug deucrictibant for hereditary angioedema treatment, though the stock has remained relatively flat since the announcement.

Pharvaris N.V., a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for hereditary angioedema and acquired angioedema, announced the pricing of an underwritten public offering of approximately 3.87 million ordinary shares at $29.68 per share, generating approximately $115 million in gross proceeds. The offering is expected to close on or about May 11, 2026. The company is preparing marketing authorization applications for deucrictibant immediate-release capsule and has an ongoing Phase 3 study (CHAPTER-3) with topline data anticipated in Q3 2026.

Director Johannes Gerardus Christiaan Petrus Schikan sold 7,100 shares of Pharvaris (1.80% of his direct holdings) for approximately $213,000 under a pre-scheduled trading plan. The modest sale is not indicative of any change in outlook. Investors should focus instead on upcoming clinical catalysts: Phase 3 CHAPTER-3 topline data expected in Q3 2026 and a planned U.S. NDA submission for deucrictibant IR in H1 2026, which will have far greater impact on the stock than insider trading activity.

Bain Capital Life Sciences Investors sold 122,106 shares of Pharvaris N.V. during Q3 2025, reducing its position value by $21.23 million while maintaining a significant stake. The sale appears to be profit-taking rather than a negative sentiment shift.

Pharvaris, a biopharmaceutical company, has priced a public offering of 8,250,000 ordinary shares at $20.00 per share and pre-funded warrants to purchase 500,000 shares, expecting to raise approximately $175 million.

Pharvaris presented data at the EAACI Congress 2025 supporting the potential of its oral bradykinin B2 receptor antagonist, deucrictibant, for the prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks.

ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the annual general meeting of shareholders will take place on Friday, June 28, 2024, at 15:00 CEST (9:00 a.m. EDT).

ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, recently presented data highlighting the unique pharmacological and clinical properties of deucrictibant for the treatment and prevention of HAE attacks at the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024.

ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at three upcoming congresses: the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024. Details of the presentations are as follows: